Semapimod hydrochloride

Research use only, not for human use.

Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production.

Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production, inhibits TLR4 signaling (IC50=0.3 uM) by targeting the TLR chaperone gp96; does not inhibit EDRF activity, inhibits nitric oxide synthesis by inflammatory macrophages; prevents the development of carrageenan-induced footpad inflammation, and conferred protection against lethal LPS challenge in mice.Irritable Bowel Syndrome Phase 2 Clinical.

——

Animal Model:Male OZ rats Dosage:5 mg/kg Administration:I.p; daily for 2 weeks Result:Restored endothelium-dependent vasorelaxation in OZ rats.Animal Model:C57Bl/6 mice (GL261 cells were orthotopically implanted) Dosage:6 mg/kg/day Administration:Intracranially for 1 week, delivered via an osmotic pump Result:Inhibited tumor cell invasion by more than 75%.

CNI 1493 | AXD-455

Immunology/Inflammation

TLR

TLR

Other Indications

Irritable Bowel Syndrome

164301-51-3

890.746

C34H56Cl4N18O2

>98% (HPLC)

In Vitro:?H2O : 2.17 mg/mL (2.44 mM)

CC(=NN=C(N)N)C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(=NN=C(N)N)C)C(=NN=C(N)N)C)C(=NN=C(N)N)C.Cl.Cl.Cl.Cl

N1,N10-bis(3-(1-(2-carbamimidoylhydrazono)ethyl)-5-(1-(2-carbamimidoylhydrazono)ethyl)phenyl)decanediamide tetrahydrochloride

(-20℃)

With Ice Pack

≥ 2 years